Friday, 30 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

Neochem Bio Solutions Investor Presentation: Key Takeaways

H1 FY27 revenue ₹68.9 cr (+50% y-o-y), PAT ₹7.8 cr (+43%), but EBITDA margin fell to 18.0% from 21.7%. Strategy centres on diversification and bio-based chemistries.

Highlights
Revenue growth+50% y-o-y to INR 68.9 cr
MarginsEBITDA margin 18.0% vs 21.7% H1 FY26

Growth

Revenue +50% y-o-y to ₹68.9 cr; EBITDA +25% to ₹12.4 cr; PAT +43% to ₹7.8 cr. Home & Personal Care up 35% to ₹9.8 cr.

Outlook

No numerical guidance given. Priorities: export expansion, new launches, Home & Personal Care growth, bio-based portfolio.

Risks

EBITDA margin down 370 bps y-o-y. Net debt/equity rose to 0.38x from 0.22x. H1 operating cash flow negative at ₹-1.0 cr.

Source

Investor Presentation filed with NSE, NSE: NEOCHEM. Summary written with AI assistance from the document.

Read the document ↗

Neochem Bio Solutions Ltd: key numbers

Share price
₹105.10
Market cap
₹179.9 Cr
Revenue (annual)
₹110.7 Cr
Net profit (annual)
₹12.03 Cr
P/E (TTM)
15.0×Sector 34.1×
Promoter holding
66.88%
FII holding
0.18%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Neochem Bio Solutions Ltd

All →